. 2016 Nov 26;8(1):1495–1507. doi: 10.18632/oncotarget.13646

Table 5. Meta-analysis association results after stratifying by first-degree family history of PCa^a^,^b.

Variant	Family	Cases (n = 5,392)			Controls (n = 4,056)			OR^d	95% CI^e	P
Variant	History	Non-carrier	Carrier	Freq^c	Non-carrier	Carrier	Freq^c	OR^d	95% CI^e	P
HOXB13 p.Gly84Glu	No	4596	49	1.05	3697	11	0.30	3.61	1.87 – 6.97	0.00013
	Yes	733	13	1.74	340	1	0.29	na^f	na^f	0.032^g
TANGO2 p.Ser17Ter	No	4531	114	2.45	3655	56	1.51	1.65	1.19 – 2.28	0.0025
	Yes	728	17	2.28	333	8	2.35	0.96	0.41 – 2.28	0.928
OR5H14 p.Met59Val	No	4526	113	2.44	3645	65	1.75	1.39	1.02 – 1.90	0.036
	Yes	724	20	2.69	335	6	1.76	1.47	0.57 – 3.82	0.427
CHAD p.Ala342Asp	No	4582	59	1.27	3675	31	0.84	1.48	0.95 – 2.30	0.080
	Yes	737	9	1.21	339	2	0.59	na^f	na^f	0.183^g

Supplemental Table S6 has the results for the FHCRC and PLCO studies separately.

Results with P < 0.05 are in bold.

Carrier frequency in percent.

Meta-analysis of age adjusted data.

95% Confidence Interval.

Meta-analysis was not be performed since one of the case-control studies had no control carriers (Supplemental Table S6).

Fisher's Exact P value comparing case and control frequencies.

Table 5. Meta-analysis association results after stratifying by first-degree family history of PCaa,b.